Sanofi stock holds steady as investors weigh India unit performance
Published on 08/26/2026 at 10:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanofi (FR0000127771) stock is drawing investor attention in late August 2026 as the market evaluates the latest quarterly performance of its Sanofi India subsidiary, which reported total income of Rs 520.80 crore for the quarter ended December 2024 and a share price of Rs 3,409.80 as of June 30, 2026.
Sanofi India numbers in focus
Recent financial data for Sanofi India highlight how this unit contributes to the broader Sanofi story. For the quarter ended December 2024, Sanofi India reported total income of Rs 520.80 crore, compared with Rs 526.30 crore in the prior quarter ended September 2024 and Rs 468.30 crore in the quarter ended June 2024, showing a modest sequential decline but clear growth against mid-2024 levels as presented in this earnings overview Sanofi India earnings and share price overview.
The same dataset shows that Sanofi India generated a basic EPS of Rs 39.64 in the quarter ended December 2024, down from Rs 44.81 in June 2024, indicating earnings per share pressure even as total income remained broadly stable across recent quarters Sanofi India quarterly EPS and margins data.
Profitability metrics also matter for investors tracking this business. Net profit margin for Sanofi India stood at 17.53 percent in the December 2024 quarter, compared with 15.62 percent in September 2024 and 22.04 percent in June 2024, underlining a margin pattern where the latest reported quarter shows improvement versus the immediately preceding period but remains below the mid-2024 peak Sanofi India margin profile across recent quarters.
Share price context and recent moves
Alongside these fundamentals, the stock performance of Sanofi India offers a concrete market signal for the wider group. As of June 30, 2026, Sanofi India shares were quoted at Rs 3,409.80, up 1.29 percent compared with the previous close of Rs 3,355.60, according to the same share price overview Sanofi India share price performance and returns data.
This price level around Rs 3,400 per share as of late June 2026 sits well above the levels seen during earlier quarters covered in the earnings table, suggesting that the market has gradually repriced the India unit higher as profitability stabilized and income trends remained resilient through 2024 and into 2026 Sanofi India multi-quarter income and price context.
For global Sanofi shareholders, the key comparative takeaway from these figures is the combination of a 1.29 percent single-day gain on June 30, 2026 and a net profit margin of 17.53 percent in the latest reported quarter, a pairing that indicates solid but not extreme valuation expansion relative to the underlying earnings profile.
Go deeper
More on Sanofi stock
Key prescription and vaccine portfolio
Sanofi generates most of its revenue from a diversified portfolio of prescription medicines, specialty care treatments, and vaccines, with its India operations contributing to this global mix through branded formulations and local-market therapies that leverage the group pipeline. Chronic-disease drugs, insulin products, and pediatric vaccines form important pillars that help stabilize revenue across economic cycles.
Sanofi stock and broader market view
While Sanofi trades primarily in Europe and in the United States through depositary receipts, the performance of Sanofi India shares as of June 30, 2026 offers one concrete reference point for investors watching the group. A local share price of Rs 3,409.80 with a 1.29 percent daily advance on that date, combined with a December 2024 net profit margin of 17.53 percent and total income of Rs 520.80 crore in the same quarter, shows how this emerging-market arm supports the global earnings base without dramatic volatility in its latest disclosed figures.
Fact box
Company: Sanofi
ISIN: FR0000127771
Sector / Industry: Pharmaceuticals
